TG Therapeutics Inc., of New York, said preliminary results of a phase II study of ublituximab, its glycoengineered anti-CD20 monoclonal antibody, showed that in patients with relapsing forms of multiple sclerosis it demonstrated rapid and robust B-cell depletion.